2. Search Result
Search Result
Results for "

Calu-3

" in MedChemExpress (MCE) Product Catalog:

45

Inhibitors & Agonists

2

Peptides

1

Inhibitory Antibodies

1

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B2247A
    PLGA (75:25)
    5+ Cited Publications

    poly(lactic-co-glycolic acid) (75:25)

    		 Biochemical Assay Reagents Others
    PLGA (75:25) is a low toxicity, biocompatible and biodegradable controlled drug delivery carrier, can achieve slow release in the organism. PLGA (75:25) is a copolymer of 75% poly lactic acid (PLA) and 25% poly glycolic acid (PGA). PLGA (75:25) has been extensively studied as delivery vehicles for agents, proteins and various other macromolecules such as DNA, RNA and peptides [3].
    PLGA (75:25)
  • HY-14909
    Bardoxolone
    Maximum Cited Publications
    23 Publications Verification

    CDDO; RTA 401

    		 Keap1-Nrf2 NF-κB SARS-CoV Apoptosis Reactive Oxygen Species (ROS) Glutathione Peroxidase Necroptosis Infection Neurological Disease Inflammation/Immunology Cancer
    Bardoxolone (CDDO; RTA 401) is a Nrf2 activator. Bardoxolone shows anti-SARS-CoV-2 3CLpro with IC50 of 27.99 μM. Bardoxolone activates the Nrf2 pathway and inhibits the NF-κB pathway. Bardoxolone can induce cells differentiation, apoptosis and shows antiproliferative activity against cancer cells. Bardoxolone can increase ROS and decrease intracellular GSH levels. Bardoxolone inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis. Bardoxolone can be used for the research of cancer, inflammation and infection, such as SARS-CoV infection and glioblastoma [3].
    Bardoxolone
  • HY-17437
    Mefloquine
    4 Publications Verification

    Mefloquin

    		 Parasite Autophagy SARS-CoV Potassium Channel ROS Kinase Infection Metabolic Disease Inflammation/Immunology Cancer
    Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K + channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research [3].
    Mefloquine
  • HY-15275
    BMS-265246
    2 Publications Verification

    		 CDK Angiotensin-converting Enzyme (ACE) Infection Cardiovascular Disease Cancer
    BMS-265246 is a potent and selective cyclin-dependent kinase CDK1 and CDK2 inhibitor, with IC50 values of 6 and 9 nM, respectively. BMS-265246 inhibits CHI3L1 (chitinase 3-like-1) stimulation of ACE2 (angiotensin converting enzyme 2) and SPP (viral spike protein priming proteases). BMS-265246 can be used for ovarian cancer and COVID-19 research [3].
    BMS-265246
  • HY-168034
    diABZI-4

    		STING Integrin NF-κB SARS-CoV Infection Inflammation/Immunology
    diABZI-4 is a STING activator and broad-spectrum antiviral agent with immunostimulatory activity. diABZI-4 triggers the TBK1-IRF3 and NF-κB signaling cascades by inducing STING oligomerization, thereby promoting the production of type I/III interferons and various proinflammatory cytokines. diABZI-4 exhibits broad-spectrum antiviral activity and effectively inhibits the replication of influenza A virus, SARS-CoV-2, herpes simplex virus, and other viruses. diABZI-4 also activates lymphocytes and macrophages to provide significant pre- and post-exposure protection in viral disease models. diABZI-4 can be used to study COVID-19, respiratory viral infections, and related immunopathological mechanisms [3] .
    diABZI-4
  • HY-120852
    JG26
    1 Publications Verification

    		 Angiotensin-converting Enzyme (ACE) MMP EGFR ERK SARS-CoV Infection Cardiovascular Disease Cancer
    JG26 is an ADAM inhibitor with IC50 values of 12 nM, 1.9 nM, and 150 nM for ADAM8, ADAM17, and ADAM10, respectively. JG26 inhibits MMP-12 with an IC50 value of 9.4 nM. JG26 inhibits AngII (HY-13948)-induced EGFR transactivation and ERK activation. JG26 increases the expression of ACE2, inhibits the cleavage of CD23, reduces the infection of SARS-CoV-2. JG26 inhibits colorectal cancer metastasis. JG26 can be used for research on Hodgkin lymphoma and vascular diseases [3] .
    JG26
  • HY-107367A
    Epertinib hydrochloride

    S-22611 hydrochloride

    		 EGFR Cancer
    Epertinib (S-22611) hydrochloride is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER4 and HER2, with IC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib hydrochloride shows potent antitumor activity . Epertinib (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Epertinib hydrochloride
  • HY-132191
    Pradimicin A

    		Fungal SARS-CoV HIV Infection
    Pradimicin A is a potent antifungal agent with a minimum inhibitory concentration (MIC) of 4 μg/mL against Candida rugosa. Pradimicin A exhibits antiviral activity against SARS-CoV, human immunodeficiency virus (HIV) and other enveloped viruses. Pradimicin A exerts its fungicidal activity through a Ca 2+-dependent mechanism, which induces fungal lysis. Pradimicin A can be used in research related to fungal infections, HIV infections and COVID-19 [3] .
    Pradimicin A
  • HY-156515
    MC-GGFG-(7ethanol-10NH2-11F-Camptothecin)

    		Drug-Linker Conjugates for ADC Cancer
    MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) is a drug-linker conjugate for ADC, formed by conjugation of 7ethanol-10NH2-11F-Camptothecin (HY-156517) with the protease-cleavable MC-GGFG linker. MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) is applicable for cancer research .
    MC-GGFG-(7ethanol-10NH2-11F-Camptothecin)
  • HY-137978
    Ezurpimtrostat
    3 Publications Verification

    GNS561

    		 SARS-CoV IFNAR Autophagy Apoptosis Infection Metabolic Disease Inflammation/Immunology Cancer
    Ezurpimtrostat (GNS561) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders [3] .
    Ezurpimtrostat
  • HY-158405
    PAV-104

    		SARS-CoV Infection
    PAV-104 inhibits SARS-CoV-2 replication, with the MOI of 0.01. PAV-104 can interact with SARS-CoV-2 nucleocapsid (N) and interfered with its oligomerization, blocking particle assembly .
    PAV-104
  • HY-W195509
    Debrisoquin hydroiodide

    Debrisoquine hydroiodide; Isocaramidine hydroiodide; Ro 5-3307/1 hydroiodide

    		 SARS-CoV Ser/Thr Protease Infection
    Debrisoquin (hydroiodide) is the hydrochloride form of Debrisoquin (HY-B1624). Debrisoquin is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner. Debrisoquin can be used for antiviral research .
    Debrisoquin hydroiodide
  • HY-B1624A
    Debrisoquin hemisulfate

    Debrisoquine hemisulfate; Isocaramidine hemisulfate; Ro 5-3307/1 hemisulfate

    		 Endogenous Metabolite Infection Cardiovascular Disease
    Debrisoquin (Isocaramidine) hemisulfate is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC50 of 22μM. Debrisoquin hemisulfate can be used for antiviral research .
    Debrisoquin hemisulfate
  • HY-P2317
    Cecropin P1, porcine

    		Bacterial Endogenous Metabolite Infection
    Cecropin P1, porcine is an antibacterial peptide that can be isolated from the upper part of the small intestine of the pig. Cecropin P1, porcine shows antibacterial activity against Gram-negative bacteria. Cecropin P1, porcine shows antiviral activity and inhibits PRRSV infection .
    Cecropin P1, porcine
  • HY-177303
    AXT-914

    		CaSR SARS-CoV Infection Metabolic Disease Endocrinology
    AXT-914 is a Calcium-sensing receptor (CaSR) inhibitor. AXT-914 has antiviral activity against the coronavirus HCoV 229E and SARS-CoV2. AXT914 reduces cytosolic calcium signalling activity of CaSR mutations. AXT-914 can be used for Bartter syndrome type 5 and autosomal dominant hypocalcemia (ADH) and coronavirus infections research .
    AXT-914
  • HY-170318
    Adhibin

    		Myosin Cancer
    Adhibin is an allosteric inhibitor for RhoGAP class IX myosin, that inhibits Myo9 ATPase in mammalian and invertebrate with IC50 of 2.5 µM and 2.6 µM. Adhibin binds to the ATPase of myosin, interfers with its motor function, blocks the RhoGTPase related signaling pathway, and affects the cell migration, adhesion and cell division. Adhibin can be used in research about cancer metastasis .
    Adhibin
  • HY-B1624
    Debrisoquin

    Debrisoquine; Isocaramidine; Ro 5-3307/1

    		 SARS-CoV Ser/Thr Protease Infection Cardiovascular Disease
    Debrisoquin (Isocaramidine) is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC50 of 22μM. Debrisoquin can be used for antiviral research .
    Debrisoquin
  • HY-163206
    SARS-CoV-2-IN-77

    		Cathepsin SARS-CoV Infection
    SARS-CoV-2-IN-77 (compound 11e) is a cathepsin L and cathepsin S inhibitor with Ki values of 111 nM and 103 nM, respectively. SARS-CoV-2-IN-77 inhibits SARS-CoV-2 with an EC50 value of 38.4 nM in Calu-3 cells without showing cytotoxicity .
    SARS-CoV-2-IN-77
  • HY-107367
    Epertinib

    S-22611

    		 EGFR Cancer
    Epertinib (S-22611) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER4 and HER2, with IC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib shows potent antitumor activity . Epertinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Epertinib
  • HY-162313
    NIP-22c

    		SARS-CoV Infection
    NIP-22c is a novel coronavirus 3CLpro inhibitor. The EC50 for Verona, Calu3, Caco2 and HBTEC-ALI were 4.6, 1.1, 0.1 and 0.6 μM, respectively. NIP-22c has antiviral activity .
    NIP-22c
  • HY-155016
    SARS-CoV-2-IN-46

    		SARS-CoV Infection
    SARS-CoV-2-IN-46 is a novel coronavirus (SARS-CoV-2) replication inhibitor with an EC50 of 0.9 μM in Calu-3 cells. SARS-CoV-2-IN-46 has antiviral activity and can be used in novel coronavirus (COVID-19) research .
    SARS-CoV-2-IN-46
  • HY-155014
    SARS-CoV-2-IN-44

    		SARS-CoV Infection
    SARS-CoV-2-IN-44, a inhibitor of SARS-CoV-2, inhibits viral replication, with an EC50 of 0.6μM. SARS-CoV-2-IN-44 has no evident cytotoxic effect in Calu-3 cells and can be used for antiviral research .
    SARS-CoV-2-IN-44
  • HY-168917
    9-Aminominocycline

    9-AMN

    		 SARS-CoV Virus Protease Infection
    9-Aminominocycline (9-AMN) is the inhibitor for SARS-CoV-2 papain-like protease (SARS-CoV-2 PLpro), inhibits its deubiquitination (DUB) activity and protease activity with IC50 of 4.55 µM and 4.15 µM. 9-Aminominocycline inhibits the SARS-CoV variants Delta and Omicron replication in Calu-3 cell with IC50 of 1.04 µM and 2.35 µM .
    9-Aminominocycline
  • HY-162719
    RH12

    		DNA/RNA Synthesis SARS-CoV Infection
    RH12 is a dual inhibitor for SARS-CoV-2 related RNA-dependent RNA polymerase (RdRp, IC50 is 4.42 nM) and human transmembrane serine protease 2 (TMPRSS2, IC50 is 4.2 nM). RH12 exhibits antiviral efficacy. RH12 inhibits viral replication and absorption, and exhibits a 90.5% virucidal effects on Vero-E6 cells. RH12 inhibits cell viability of Calu-3 with an IC50 of 17.5 nM .
    RH12
  • HY-178156
    DHODH-IN-31

    		Dihydroorotate Dehydrogenase SARS-CoV Infection
    DHODH-IN-31 is a human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 0.59 μM. DHODH-IN-31 exhibits antiviral activity. DHODH-IN-31 can be used for the research of infection, such as SARS-CoV-2 .
    DHODH-IN-31
  • HY-157805
    PROTAC SARS-CoV-2 Mpro degrader-2

    		PROTACs SARS-CoV Infection
    PROTAC SARS-CoV-2 Mpro degrader-2 (Compound 6) is a potent PROTAC degrader of SARS-CoV-2 M pro. PROTAC SARS-CoV-2 Mpro degrader-2 has broad-spectrum antiviral activity against CoVs, including SARS-CoV-2 (EC50 = 10.8 μM), HCoV-OC43 (EC50 = 1.6 μM) and HCoV-229E (EC50 = 6.5 μM). PROTAC SARS-CoV-2 Mpro degrader-2 exhibits potent activity against SARS-CoV-2 in Calu-3 cells, with an EC50 of 0.89 μM .
    PROTAC SARS-CoV-2 Mpro degrader-2
  • HY-176280
    SARS-CoV-2-IN-115

    		SARS-CoV Dihydroorotate Dehydrogenase DNA/RNA Synthesis Infection
    SARS-CoV-2-IN-115 (Compound 3e) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-115 has potent antiviral activity against SARS-CoV-2 in infected Calu-3 cells (EC50: 1.7  μM). SARS-CoV-2-IN-115 effectively inhibits the activity of human dihydroorotate dehydrogenase (HsDHODH) (IC50: 1.5  μM). SARS-CoV-2-IN-115 preserves immune response without antiproliferative effects on CD4 T cells .
    SARS-CoV-2-IN-115
  • HY-17437R
    Mefloquine (Standard)

    Mefloquin (Standard)

    		 Parasite Autophagy SARS-CoV Potassium Channel ROS Kinase Reference Standards Infection Metabolic Disease Inflammation/Immunology Cancer
    Mefloquine (Standard) is the analytical standard of Mefloquine. This product is intended for research and analytical applications. Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research [3].
    Mefloquine (Standard)
  • HY-155015
    SARS-CoV-2-IN-45

    		SARS-CoV Infection
    SARS-CoV-2-IN-45 (Compound 8p) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-45 inhibits SARS-CoV-2 replication in Calu-3 cell with an EC50 of 0.5 μM, and has no evident cytotoxic effect .
    SARS-CoV-2-IN-45
  • HY-163029
    CTSL/B-IN-1

    		Cathepsin SARS-CoV Infection
    CTSLCTSB-IN-1 (compound 212-148) is a bispecific inhibitor of host viral spike cleaver proteins CTSL/CTSB and TMPRSS2 with IC50s of 2.13/64.07 nM and 1.38 μM, respectively. CTSLCTSB-IN-1 blocks two relevant SARS-CoV-2 viral entry pathways by inhibiting the viral spike cleavage and can be applied to anti-SARS-CoV-2 research .
    CTSL/B-IN-1
  • HY-173459
    N-0920

    		SARS-CoV Infection
    N-0920 is a potent TMPRSS2 inhibitor with an IC50 of 0.35 nM. N-0920 effectively inhibits SARS-CoV-2 variants EG.5.1 and JN.1 entry in Calu-3 cells, with picomolar EC50s values of 300 pM and 90 pM, respectively .
    N-0920
  • HY-156325
    SARS-CoV-2-IN-62

    		SARS-CoV Infection
    SARS-CoV-2-IN-62 (Compound R3b) is an inhibitor of SARS-CoV-2 replication and has low cytotoxicity. SARS-CoV-2-IN-62 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC50 values of 2.97 μM and 3.82 μM, respectively .
    SARS-CoV-2-IN-62
  • HY-156337
    SARS-CoV-2-IN-63

    		SARS-CoV Infection
    SARS-CoV-2-IN-63 (Compound R3e) is an inhibitor of SARS-CoV-2 replication and has low cytotoxicity. SARS-CoV-2-IN-63 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC50 values of 1.99 μM and 1.92 μM, respectively .
    SARS-CoV-2-IN-63
  • HY-156441
    SARS-CoV-2-IN-65

    		SARS-CoV Infection
    SARS-CoV-2-IN-65 (compound 2f (81)) is a potent,orally active and reversible SARS-CoV-2 entry inhibitor. SARS-CoV-2-IN-65 inhibits the pseudovirus entry in a ACE2-dependent pathway, via mainly inhibiting RBD:ACE2 interaction and TMPRSS2 activity in Calu-3 cells .
    SARS-CoV-2-IN-65
  • HY-P991233
    BAT1006

    		EGFR Cancer
    BAT1006 is a monoclonal antibody targeting HER2 extracellular domain II with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for the study of HER2-positive locally advanced/metastatic solid tumors. BAT1006 has an approximately 5-fold enhanced ADCC effect compared to pertuzumab (HY-P9912) and exhibits potent anti-tumor activity in the HER2-positive Calu-3 xenograft mouse model .
    BAT1006
  • HY-149304
    SARS-CoV-2-IN-40

    		SARS-CoV Infection
    SARS-CoV-2-IN-40 (Compound 19) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC50s of 100 nM and 160 nM respectively .
    SARS-CoV-2-IN-40
  • HY-162492
    Influenza A virus-IN-14

    		Influenza Virus Infection
    Influenza A virus-IN-14 (Compound 37) is an inhibitor for influenza virus type A (IAV), which inhibits H1N1 with an EC50 of 23 nM. Influenza A virus-IN-14 exhibits low cytotoxicity with CC50 of more than 100 μM. Influenza A virus-IN-14 inhibits cytopathic effect and improves the survival rates of cell Calu3. Influenza A virus-IN-14 exhibits synergistic activity with the neuraminidase inhibitor Oseltamivir (HY-13317). Influenza A virus-IN-14 exhibits poor pharmacokinetic properties in CD-1 mouse .
    Influenza A virus-IN-14
  • HY-176453
    Allobetulone

    N066-0059

    		 Chloride Channel Cancer
    Allobetulone (N066-0059) is a TMEM16A inhibitor (IC50: 0.24 µM). Allobetulone (N066-0059) can be used in anti-cancer research .
    Allobetulone
  • HY-155186
    SARS-CoV-2 3CLpro-IN-19

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide SARS-CoV-2 3CLpro inhibitor (IC50s: 0.7 μM). SARS-CoV-2 3CLpro-IN-19 has broad-spectrum activity against Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) infection in human cells, with EC50 values between 30-69 nM .
    SARS-CoV-2 3CLpro-IN-19
  • HY-B1624C
    Debrisoquin hydrobromide

    Debrisoquine hydrobromide; Isocaramidine hydrobromide; Ro 5-3307/1 hydrobromide

    		 SARS-CoV Ser/Thr Protease Infection
    Debrisoquine (Ro 5-3307/1) hydrobromide is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC50 of 22μM. Debrisoquine hydrobromide can be used for antiviral research .
    Debrisoquin hydrobromide
  • HY-170894
    SARS-CoV-2 Mpro-IN-37

    		SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-37 (compound 8r) is a SARS-CoV-2 main protease (M pro) inhibitor, with an IC50 of 0.0199 μM. SARS-CoV-2 Mpro-IN-37 inhibits SARS-CoV-1 M pro and MERS-CoV M pro with IC50s of 0.00945 and 0.111 μM, respectively. SARS-CoV-2 Mpro-IN-37 displays high antiviral activity in the nanomolar range without showing cellular toxicity .
    SARS-CoV-2 Mpro-IN-37
  • HY-181165
    SB2960

    		PKC SARS-CoV IFNAR Infection
    SB2960 is a receptor for activated protein C kinase 1 (RACK1) binder with a human KD of 5.65 μM. SB2960 can promote stress granule (SG) formation and exhibit potent antiviral activity across diverse viral species. SB2960 suppresses viral replication with minimal cytotoxicity by modulating host antiviral immune responses. SB2960 increases the thermal stability of RACK1 and reduces SARS-CoV-2 N protein levels. SB2960 enhances type I interferon (IFN-β) expression and inhibits RIG-I, ISG56, and RANTES expression. SB2960 can be used for the research of virus infection .
    SB2960
  • HY-107367AR
    Epertinib hydrochloride (Standard)

    S-22611 hydrochloride (Standard)

    		 Reference Standards EGFR Cancer
    Epertinib hydrochloride (Standard) (S-22611 hydrochloride (Standard)) is the analytical standard of Epertinib (hydrochloride) (HY-107367A). This product is intended for research and analytical applications. Epertinib (S-22611) hydrochloride is a potent, orally active, reversible, and selective tyrosine Kinase inhibitor of EGFR, HER4 and HER2, with IC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib hydrochloride shows potent antitumor activity . Epertinib (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Epertinib hydrochloride (Standard)
  • HY-181647
    LasB-IN-3

    		Bacterial Elastase Infection
    LasB-IN-3 is a protease elastase (LasB) inhibitor of Pseudomonas aeruginosa with an IC50 value of 8.5 nM. LasB-IN-3 shows an IC50 of 58.9 nM for the Met128Val mutant. LasB-IN-3 binds to active sites of wild-type and Met128Val mutant LasB, coordinates zinc ions, forms hydrogen bonds and CH-π interactions, and inhibits LasB proteolytic activity. LasB-IN-3 increases survival rate in LasB-induced acute lung injury mice models. LasB-IN-3 can be used for the research of Pseudomonas aeruginosa infection .
    LasB-IN-3
  • HY-182913
    SARS-CoV-2-IN-122

    		SARS-CoV Infection
    SARS-CoV-2-IN-122 is a SARS-CoV-2 inhibitor by targeting the S2 subunit of the spike protein. SARS-CoV-2-IN-122 interacts with residues linked to membrane fusion-associated conformational rearrangements, interfering with viral entry events. SARS-CoV-2-IN-122 inhibits SARS-CoV-2 replication, lacks direct virucidal activity, and does not impair viral-host cell attachment. SARS-CoV-2-IN-122 exhibits activity against SARS-CoV-2 variants including B.1 and Omicron (BA.2.86.1). SARS-CoV-2-IN-122 can be used for the research of coronavirus disease 2019 (COVID-19) .
    SARS-CoV-2-IN-122

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: